Faricimab - CAS 1607793-29-2

Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.

RAAS, VEGFR

Endocrinology/Hormones, Angiogenesis, Tyrosine Kinase/Adaptors

1607762

>95%

-20°C

Ice Packs

Inhibitory Antibodies